Which region accounted for the largest share in Global Cancer Cachexia Market?

The market size in North America is $0.90 billion by 2022. The dominance of this segment is driven by high prevalence of cancer cachexia, increasing awareness of cancer supportive care as well as, availability of adequate reimbursement models in the US. and Canada Greater affordability among patients with results in this sector dominance. Cancer cachexia market report scope includes the regional breakdown, revealing that North America dominated the industry by 2022. Increase in awareness programs related to cancer care is driving the growth of the market regionally in the 19th century. The increasing number of pipeline drugs in Phase III clinical trials is also expected to drive the cancer cachexia market share where these drugs are likely to hit the market in the next few years.

Cancer Cachexia Market Size, Share, Growth Analysis, By Product(Progestogens, Corticosteroids, Combination Therapies, and Others), By Distribution Channels(Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Mechanism of Action(Appetite Stimulators and Weight Loss Stabilizers), By Region - Industry Forecast 2025-2032

Q: What is the global market size of Cancer Cachexia Market?

Global Cancer Cachexia Market size was valued at USD 2.31 Billion in 2022 and is poised to grow from USD 2.42 Billion in 2023 to USD 3.47 Billion by 2031, growing at a CAGR of 4.6% in the forecast period (2024-2031)

Q: Who are the key vendors in the Global Cancer Cachexia Market?

The competitive environment of the Global Cancer Cachexia Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Established organizations within the industry leverage techniques inclusive of product innovation, strategic partnerships, and mergers and acquisitions to strengthen their market position. Additionally, the market is witnessing elevated opposition from local and neighborhood producers supplying cost-powerful options. 'Aeterna Zentaris', 'Aphios Corporation', 'Bristol-Myers Squibb Company', 'Pfizer Inc.', 'Helsinn Group', 'Merck KGaA', 'Artelo Biosciences Inc.', 'NGM Biopharmaceuticals', 'Aveo Oncology ', 'Aavogen Inc. ', 'Green Cross Wellbeing Corporation', 'Cannabics Pharmaceuticals Inc.', 'TCI Peptide Therapeutics', 'Fresenius Kabi', 'Tetra Bio-Pharma', 'Actimed Therapeutics'.

Report ID: SQMIG35A2857 | Region: Global | Published Date: March, 2024
Pages: 185 | Tables: 89 | Figures: 72

Cancer Cachexia Market Insights

Cancer Cachexia Market size was valued at USD 2.42 Billion in 2023 and is poised to grow from USD 2.53 Billion in 2024 to USD 3.63 Billion by 2032, growing at a CAGR of 4.6% during the forecast period (2025-2032).

According to data released by the National Center for Biotechnology Information (NCBI), the prevalence of cachexia in patients with advanced cancer is estimated at 80.0%. Globally, cachexia accounts for 20.0% of cancer deaths. It is a wasting disorder characterized by weight loss, anorexia, osteoporosis and anemia in patients. It is commonly associated with chronic diseases such as cancer, renal failure, chronic obstructive pulmonary disease (COPD), and HIV. Cancer-induced cachexia is associated with the presence of tumors. According to the Cancer Cachexia Hub, the condition affects an estimated 1.3 million cancer patients in the US. only annually.

Cancer cachexia is a multifaceted disease characterized by involuntary weight loss, muscle wasting, and metabolic abnormalities commonly associated with cancer cachexia market treatment experiences and induces a variety of growth stimulants opportunities impact the event and contribute to the overall cancer cachexia market growth and potential. The global increase in cancer implies a corresponding increase in the prevalence of cancer cachexia, thus increasing the market potential of cancer cachexia. The increasing prevalence of cancer establishes a large patient cohort, promoting opportunities for the development of potential therapies and therapeutic interventions targeting cancer cachexia. Older individuals are more susceptible to cancer, increasing the risk of cancer cachexia. The aging population in many countries highlights huge market opportunities for therapies that address cancer-related challenges including cachexia, thereby driving cancer cachexia into the market.

Cancer Cachexia Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Cancer Cachexia Market size was valued at USD 2.31 Billion in 2022 and is poised to grow from USD 2.42 Billion in 2023 to USD 3.47 Billion by 2031, growing at a CAGR of 4.6% in the forecast period (2024-2031)

The competitive environment of the Cancer Cachexia Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Established organizations within the industry leverage techniques inclusive of product innovation, strategic partnerships, and mergers and acquisitions to strengthen their market position. Additionally, the market is witnessing elevated opposition from local and neighborhood producers supplying cost-powerful options. 'Aeterna Zentaris', 'Aphios Corporation', 'Bristol-Myers Squibb Company', 'Pfizer Inc.', 'Helsinn Group', 'Merck KGaA', 'Artelo Biosciences Inc.', 'NGM Biopharmaceuticals', 'Aveo Oncology', 'Aavogen Inc.', 'Green Cross Wellbeing Corporation', 'Cannabics Pharmaceuticals Inc.', 'TCI Peptide Therapeutics', 'Fresenius Kabi', 'Tetra Bio-Pharma', 'Actimed Therapeutics'

Current treatment options for cachexia in cancer patients are limited to drugs such as progestogens, corticosteroids, and others. These drugs have shown efficacy in the treatment of cancer-induced cachexia, although there are clinical differences in treatment outcomes and no drug candidates are currently approved specifically for this condition. This increases the gap in therapeutic options, which market players are aiming to fill through R&D and the introduction of new drugs in the market.

In many cases, traditional approaches to treating patients with single-drug interventions provided limited therapeutic benefit. Also, due to the lack of approved drugs for this condition, healthcare providers have been seen turning to combination therapies to treat illness including both pharmacological and non-pharmacological. Clinical trials show significant improvement in body does not deny (LBM) in treated patients and combination therapies. Thus, such outcomes as the popularity of health professionals increase the acceptability of combination therapy among patient populations and drive the demand for cancer cachexia treatments in the market.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Cancer Cachexia Market Insights

Cancer Cachexia Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Cancer Cachexia Market?

Who are the key vendors in the Cancer Cachexia Market?

What is the key driver of Cancer Cachexia Market?

What is the key market trend for Cancer Cachexia Market?

Which region accounted for the largest share in Cancer Cachexia Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300